Durvalumab: beside an established treatment under test

78 studies: an approved drug, surgery or radiation is what the study tests. Page 1 of 1. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.

• PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver CancerRecruitingNCT07884877Phase 2Report a problem
• CLEAR-Lung III: Circulating Tumor DNA-Guided Consolidation Chemotherapy and ImmunotherapyNot yet recruitingNCT07858253Phase 2Report a problem
• Histotripsy in Biliary Tract CancerRecruitingNCT07853690Not applicableReport a problem
• Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal CancerRecruitingNCT07700420Phase 1Report a problem
• Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC TrialNot yet recruitingNCT07639528Phase 2Report a problem
• Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung CancerNot yet recruitingNCT07637513Phase 3Report a problem
• GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular CancerRecruitingNCT07627191Early Phase 1Report a problem
• RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) TrialNot yet recruitingNCT07625930Phase 2Report a problem
• A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung CancerRecruitingNCT07603856Phase 2Report a problem
• An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.RecruitingNCT07282262Phase 2Report a problem
• Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic CholangiocarcinomaRecruitingNCT07235007Not applicableReport a problem
• Impact of Circadian Rhythm on ImmunotherapyRecruitingNCT07224971Phase 2Report a problem
• Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal AdenocarcinomaRecruitingNCT07222657Phase 2Report a problem
• SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and AnxietyRecruitingNCT07174947Phase 2Report a problem
• Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic TreatmentNot yet recruitingNCT07168668Phase 2Report a problem
• Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialRecruitingNCT07166406Phase 3Report a problem
• Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular CarcinomaRecruitingNCT06904170Phase 2/3Report a problem
• STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular CarcinomaRecruitingNCT06880523Phase 2Report a problem
• HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic CholangiocarcinomaRecruitingNCT06858735Phase 2Report a problem
• Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCCRecruitingNCT06841172Phase 3Report a problem
• First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.RecruitingNCT06840782Phase 3Report a problem
• Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLCRecruitingNCT06810609Phase 2Report a problem
• Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)Not yet recruitingNCT06719336Phase 3Report a problem
• A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract CancersRecruitingNCT06611345Not applicableReport a problem
• Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic CholangiocarcinomaNot yet recruitingNCT06567600Phase 2Report a problem
• Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung CancerRecruitingNCT06529081Not applicableReport a problem
• Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)Not yet recruitingNCT06502080Phase 2Report a problem
• IMPT Dose Escalation for NSCLC (HyDose)RecruitingNCT06484491Not applicableReport a problem
• Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract CancerRecruitingNCT06274879Phase 2Report a problem
• Radiation Therapy in Unresectable Gall Bladder CancerRecruitingNCT06214572Phase 2/3Report a problem
• PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLCRecruitingNCT06102057Phase 2Report a problem
• Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction ImmunochemotherapyNot yet recruitingNCT06031597Phase 3Report a problem
• Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerRecruitingNCT05624996Phase 3Report a problem
• Combining ICI With SBRT or HypoFrx-RT for ES NSCLCNot yet recruitingNCT05451173Phase 1/2Report a problem
• Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With DurvalumabEnrolling by invitationNCT05303532Phase 3Report a problem
• Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung CancerRecruitingNCT04992780Phase 2Report a problem
• Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCRecruitingNCT04686305Phase 1Report a problem
• A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal CancerNot yet recruitingNCT04621370Phase 2Report a problem
• Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCRecruitingNCT04585490Phase 3Report a problem
• Durvalumab and Stereotactic Radiotherapy for Advanced NSCLCTerminatedNCT04786093Phase 2Results postedReport a problem
• Durvalumab Long-Term Safety and Efficacy StudyCompletedNCT04078152Phase 4Results postedReport a problem
• Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung CancerCompletedNCT03916419Phase 2Results postedReport a problem
• Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected MutationsActive, not recruitingNCT03842228Phase 1Results postedReport a problem
• Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)Active, not recruitingNCT03775486Phase 2Results postedReport a problem
• A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)Active, not recruitingNCT03459846Phase 2Results postedReport a problem
• Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLCActive, not recruitingNCT03141359Phase 2Results postedReport a problem
• Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLCActive, not recruitingNCT03057106Phase 2Results postedReport a problem
• Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung CancerActive, not recruitingNCT02888743Phase 2Results postedReport a problem
• A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung CancerCompletedNCT02492867Not applicableResults postedReport a problem
• Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation TherapyTerminatedNCT02452463Phase 2Results postedReport a problem
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)Active, not recruitingNCT07005128Phase 3Report a problem
• Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 MutationActive, not recruitingNCT06501625Phase 1/2Report a problem
• Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabActive, not recruitingNCT06211036Phase 3Report a problem
• Tumor Treating Fields for Locally Advanced NSCLCWithdrawnNCT06124118Phase 1Report a problem
• ......SMARTEST Trial......CompletedNCT05380713Phase 2Report a problem
• Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract CancerCompletedNCT05239169Phase 2Report a problem
• Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung CancerTerminatedNCT05223647Phase 3Report a problem
• Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial CarcinomaCompletedNCT05154994Phase 1Report a problem
• A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung CancerCompletedNCT04905316Phase 2Report a problem
• Lung Cancer With Copanlisib and DurvalumabCompletedNCT04895579Phase 1Report a problem
• Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain MetastasesWithdrawnNCT04889066Phase 2Report a problem
• The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract CancersActive, not recruitingNCT04781192Phase 1/2Report a problem
• Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With DurvalumabTerminatedNCT04748419Phase 1/2Report a problem
• Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)Active, not recruitingNCT04597671Phase 3Report a problem
• Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical CystectomyTerminatedNCT04579133Phase 2Report a problem
• A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerActive, not recruitingNCT04556773Phase 1Report a problem
• A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast CancerActive, not recruitingNCT04538742Phase 1/2Report a problem
• Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC PatientsWithdrawnNCT04470674Phase 2Report a problem
• Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)Active, not recruitingNCT04379596Phase 2Report a problem
• Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for ChemotherapyCompletedNCT04351256Phase 2Report a problem
• Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic CancerCompletedNCT04257448Phase 1/2Report a problem
• A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular CarcinomaTerminatedNCT03970616Phase 1/2Report a problem
• Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast CancerWithdrawnNCT03872505Phase 2Report a problem
• Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLCTerminatedNCT03818776Early Phase 1Report a problem
• Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell CarcinomaCompletedNCT03618654Early Phase 1Report a problem
• Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell LungCompletedNCT03589547Phase 2Report a problem
• Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian CancerCompletedNCT03430518Phase 1Report a problem
• Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung CancerActive, not recruitingNCT01993810Phase 3Report a problem

← Durvalumab